Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HemoShear's Human Disease Model Validated By Takeda NASH Deal

Executive Summary

Emerging Company Profile: HemoShear thinks its REVEAL-tx platform can identify novel targets and validate drug candidates better than existing bench research methods. Japan’s Takeda is betting in a new collaboration that HemoShear can deliver novel targets in NASH.

Advertisement

Related Content

Deal Watch: Boehringer Teams Up In CNS Disorders Again, This Time With Domain
Deal Watch: Syndax Gets Former Vitae Leukemia Program From Allergan
Genfit's Enrollment Delay In NASH May Aid Intercept's First-To-Market Goal
The NASH Pipeline: Replete With Targets And New Compounds

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099671

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel